Or it's just BAU, LC has mentioned a month ago for the market to...

Or it's just BAU, LC has mentioned a month ago for the market to wait for new data cut. What do you want her to do a month later? Do more interviews and tell the market to wait for new data cut again? IMU has achieved excellent clinical update to date despite this very restricted requirement for the clinical trial which was probably required to be granted FDA IND and they've presented these same excellent clinical update data to another major conference as recently as a few weeks ago. It highly doubtful there will be restrictions in place for cancer patients to use the drug after demonstrating safety and efficacy and clearly risk will outweigh the benefit to allow patient in much early stage of cancer so a much healthier immune system to use the drug.